362 related articles for article (PubMed ID: 18823530)
1. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.
Lundgren K; Holm K; Nordenskjöld B; Borg A; Landberg G
Breast Cancer Res; 2008; 10(5):R81. PubMed ID: 18823530
[TBL] [Abstract][Full Text] [Related]
2. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
[TBL] [Abstract][Full Text] [Related]
3. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
4. RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.
Keilty D; Buchanan M; Ntapolias K; Aleynikova O; Tu D; Li X; Shepherd L; Bramwell V; Basik M
PLoS One; 2013; 8(12):e81740. PubMed ID: 24367492
[TBL] [Abstract][Full Text] [Related]
5. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
6. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.
Schraml P; Schwerdtfeger G; Burkhalter F; Raggi A; Schmidt D; Ruffalo T; King W; Wilber K; Mihatsch MJ; Moch H
Am J Pathol; 2003 Sep; 163(3):985-92. PubMed ID: 12937139
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.
Holm K; Staaf J; Jönsson G; Vallon-Christersson J; Gunnarsson H; Arason A; Magnusson L; Barkardottir RB; Hegardt C; Ringnér M; Borg A
Breast Cancer Res Treat; 2012 Jun; 133(2):583-94. PubMed ID: 22002566
[TBL] [Abstract][Full Text] [Related]
8. Stromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer.
Lundgren K; Tobin NP; Lehn S; Stål O; Rydén L; Jirström K; Landberg G
J Mol Diagn; 2011 May; 13(3):340-51. PubMed ID: 21497294
[TBL] [Abstract][Full Text] [Related]
9. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei.
Bautista S; Theillet C
Genes Chromosomes Cancer; 1998 Aug; 22(4):268-77. PubMed ID: 9669664
[TBL] [Abstract][Full Text] [Related]
10. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
11. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG
Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma.
Greer RO; Said S; Shroyer KR; Marileila VG; Weed SA
Oral Oncol; 2007 Sep; 43(8):735-41. PubMed ID: 17113340
[TBL] [Abstract][Full Text] [Related]
13. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Lundgren K; Brown M; Pineda S; Cuzick J; Salter J; Zabaglo L; Howell A; Dowsett M; Landberg G;
Breast Cancer Res; 2012 Apr; 14(2):R57. PubMed ID: 22475046
[TBL] [Abstract][Full Text] [Related]
14. Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer.
Gibcus JH; Menkema L; Mastik MF; Hermsen MA; de Bock GH; van Velthuysen ML; Takes RP; Kok K; Alvarez Marcos CA; van der Laan BF; van den Brekel MW; Langendijk JA; Kluin PM; van der Wal JE; Schuuring E
Clin Cancer Res; 2007 Nov; 13(21):6257-66. PubMed ID: 17975136
[TBL] [Abstract][Full Text] [Related]
15. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
Mrhalová M; Kodet R; Strnad P
Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
[TBL] [Abstract][Full Text] [Related]
16. MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer.
Janssen JW; Cuny M; Orsetti B; Rodriguez C; Vallés H; Bartram CR; Schuuring E; Theillet C
Int J Cancer; 2002 Dec; 102(6):608-14. PubMed ID: 12448002
[TBL] [Abstract][Full Text] [Related]
17. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
[TBL] [Abstract][Full Text] [Related]
18. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
Jirström K; Stendahl M; Rydén L; Kronblad A; Bendahl PO; Stål O; Landberg G
Cancer Res; 2005 Sep; 65(17):8009-16. PubMed ID: 16140974
[TBL] [Abstract][Full Text] [Related]
19. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL
Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415
[TBL] [Abstract][Full Text] [Related]
20. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D
Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
